Kynam Capital Management, LP - 10 Aug 2023 Form 4 Insider Report for 2seventy bio, Inc. (TSVT)

Reporting relationship: 10%+ Owner
Issuer ticker: TSVT
Reported as of: 10 Aug 2023
Net transaction value: +$3,564,315
SEC form: 4
Accepted by SEC: 14 Aug 2023, 20:51:53 UTC
Source filing: View source filing
Reporting owner signature: KYNAM CAPITAL MANAGEMENT, LP, By: KYNAM CAPITAL MANAGEMENT GP, LLC, By: /s/ Yue Tang, Yue Tang, Managing Member

Key filing fact

Kynam Capital Management, LP filed Form 4 for 2seventy bio, Inc. (TSVT) on 14 Aug 2023.

Key facts

This page summarizes Kynam Capital Management, LP's Form 4 filing for 2seventy bio, Inc. (TSVT).
6 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 14 Aug 2023, 20:51.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: +$3,564,315.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TSVT transaction

Common Stock, par value $0.0001 per share

Purchase

Transaction value: $1,063,260
Shares: +179,000
Change %: +3.2%
Price: $5.94
Shares after: 5,703,825
Date: 10 Aug 2023
Ownership: See Footnote
Footnotes: F1

TSVT transaction

Common Stock, par value $0.0001 per share

Purchase

Transaction value: $290,000
Shares: +50,000
Change %: +0.88%
Price: $5.80
Shares after: 5,753,825
Date: 10 Aug 2023
Ownership: See Footnote
Footnotes: F1

TSVT transaction

Common Stock, par value $0.0001 per share

Purchase

Transaction value: $585,000
Shares: +100,000
Change %: +1.7%
Price: $5.85
Shares after: 5,853,825
Date: 10 Aug 2023
Ownership: See Footnote
Footnotes: F1

TSVT transaction

Common Stock, par value $0.0001 per share

Purchase

Transaction value: $596,000
Shares: +100,000
Change %: +1.7%
Price: $5.96
Shares after: 5,953,825
Date: 10 Aug 2023
Ownership: See Footnote
Footnotes: F1

TSVT transaction

Common Stock, par value $0.0001 per share

Purchase

Transaction value: $515,027
Shares: +86,414
Change %: +1.7%
Price: $5.96
Shares after: 5,142,111
Date: 10 Aug 2023
Ownership: Direct
Footnotes: F2

TSVT transaction

Common Stock, par value $0.0001 per share

Purchase

Transaction value: $515,027
Shares: +86,414
Change %: +1.7%
Price: $5.96
Shares after: 5,142,111
Date: 10 Aug 2023
Ownership: See Footnote
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The reported securities are owned directly by Kynam Global Healthcare Master Fund, LP (the "Master Fund"), a private investment fund managed by Kynam Capital Management, LP (the "Adviser"), and separately managed account clients of the Adviser and may be deemed to be indirectly beneficially owned by (i) the Adviser, (ii) Kynam Capital Management GP, LLC (the "Adviser GP"), the general partner of the Adviser and (iii) Yue Tang, the managing member of the Adviser GP. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Footnote F2

The reported securities are directly owned by the Master Fund. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Footnote F3

The reported securities are owned directly by the Master Fund and may be deemed to be indirectly beneficially owned by Kynam Fund GP, LLC, the general partner of the Master Fund. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.